Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung CancerGlobeNewsWire • 09/09/24
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMOGlobeNewsWire • 09/09/24
Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 2024 Healthcare Conference (Transcript)Seeking Alpha • 09/05/24
Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/05/24
Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron under Ongoing CollaborationBusiness Wire • 09/04/24
Koneksa Announces Regeneron Joins Data Syndication Program for Parkinson's Digital Biomarkers StudyBusiness Wire • 09/03/24
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaGlobeNewsWire • 08/26/24
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory DiseasesGlobeNewsWire • 08/26/24